"Lest we forget you - methylene blue..."

Neurobiology of Aging

Volumn 32, Issue 12, 2011, Pages 2325.e7-2325.e16

  Schirmer, R Heiner ^a   Adler, Heike ^a   Pickhardt, Marcus ^b,c   Mandelkow, Eckhard ^b,c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b MAX PLANCK UNIT FOR STRUCTURAL MOLECULAR BIOLOGY   (Germany)

^c GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

Alzheimer's disease; History; Malaria therapy; Medical application; Methylene blue; Prodrug of azure B; Tau aggregation inhibitor

Indexed keywords

AMYLOID BETA PROTEIN; AZURE B; GLUTATHIONE REDUCTASE; IFOSFAMIDE; METHYLENE BLUE; PYOCYANINE; REMBER; RIVASTIGMINE; SELENIUM; SEROTONIN UPTAKE INHIBITOR; TAU PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; BACTERIUM IDENTIFICATION; DEPRESSION; DISINFECTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG INDICATION; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG URINE LEVEL; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; GIEMSA STAIN; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; GOOD MANUFACTURING PRACTICE; HEREDITARY METHEMOGLOBINEMIA; HISTOCHEMISTRY; HUMAN; INHIBITION KINETICS; MALARIA; MALARIA FALCIPARUM; METHEMOGLOBINEMIA; MYCOBACTERIUM TUBERCULOSIS; NEUROTOXICITY; NONHUMAN; PATIENT COMPLIANCE; PLASMODIUM FALCIPARUM; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN AGGREGATION; SHOCK; UNITED STATES; URINALYSIS; URINARY TRACT INFECTION; VASOPLEGIA;

EID: 79955674414     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2010.12.012     Document Type: Article

References (82)

1. Ahuja E.G., Janning P., Mentel M., Graebsch A., Breinbauer R., Hiller W., Costisella B., Thomashow L.S., Mavrodi D.V., Blankenfeldt W. PhzA/B catalyzes the formation of the tricycle in phenazine biosynthesis. J. Am. Chem. Soc 2008, 130:17053-17061.
2. Akoachere M., Buchholz K., Fischer E., Burhenne J., Haefeli W.E., Schirmer R.H., Becker K. In vitro assessment of methylene blue on chloroquine-sensitive and -resistant Plasmodium falciparum strains reveals synergistic action with artemisinins. Antimicrob. Agents Chemother 2005, 49:4592-4597.
3. Arai T., Hasegawa M., Nonoka T., Kametani F., Yamashita M., Hosokawa M., Niizato K., Tsuchiya K., Kobayashi Z., Ikeda K., Yoshida M., Onaya M., Fujishiro H., Akiyama H. Phosphorylated and cleaved TDP-43 in ALS, FTLD and other neurodegenerative disorders and in cellular models of TDP-43 proteinopathy. Neuropathology 2010, 30:170-181.
4. Atamna H., Kumar R. Protective role of methylene blue in Alzheimer's disease via mitochondria and cytochrome c oxidase. J. Alzheimers Dis 2010, 20:S439-S452.
5. Atamna H., Krugliak M., Shalmiev G., Deharo E., Pescarmona G., Ginsburg H. Mode of antimalarial effect of methylene blue and some of its analogues on Plasmodium falciparum in culture and their inhibition of P. vinckei petteri and P. yoelii nigeriensis in vivo. Biochem. Pharmacol 1996, 51:693-700.
6. Atamna H., Nguyen A., Schultz C., Boyle K., Newberry J., Kato H., Ames B.N. Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways. FASEB J 2008, 22:703-712.
7. Barcia J.J. The Giemsa stain: its history and applications. Int. J. Surg. Pathol 2007, 15:292-296.
8. Bodoni P. Dell'azione sedativa del bleu di metilene in varie forme di psicosi. Clin. Med. Ital 1899, 21:217-222.
9. Bountogo M., Zoungrana A., Coulibaly B., Klose C., Mansmann U., Mockenhaupt F.P., Burhenne J., Mikus G., Walter-Sack I., Schirmer R.H., Sié A., Meissner P., Müller O. Efficacy of methylene blue monotherapy in semi-immune adults with uncomplicated falciparum malaria: a controlled trial in Burkina Faso. Trop. Med. Int. Health 2010, 15:713-717.
10. Bruchey A.K., Gonzales-Lima F. Behavioral, physiological and biochemical hormetic responses to the autoxidizable dye methylene blue. Am. J. Pharmacol. Toxicol 2008, 3:72-79.
11. Buchholz K., Schirmer R.H., Eubel J.K., Akoachere M.B., Dandekar T., Becker K., Gromer S. Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum. Antimicrob. Agents Chemother 2008, 52:183-191.
12. Bulic B., Pickhardt M., Mandelkow E.M., Mandelkow E. Tau protein and tau aggregation inhibitors. Neuropharmacology 2010, 59:276-289.
13. Burrows G.E. Methylene blue: effects and disposition in sheep. J. Vet. Pharmacol. Ther 1984, 7:225-231.
14. Cajal S. El azul de metileno en los centros nerviosos. Rev. Trimest. Microgr 1896, 1:151-203.
15. Cardamatis A. Methylene blue in grave malaria cachexia. JAMA 1900, 34:1408-1409.
16. Cawein M., Behlen C.H., Lappat E.J., Cohn J.E. Hereditary diaphorase deficiency and methemoglobinemia. Arch. Intern. Med 1964, 113:578-585.
17. Chang E., Congdon E.E., Honson N.S., Duff K.E., Kuret J. Structure-activity relationship of cyanine tau aggregation inhibitors. J. Med. Chem 2009, 52:3539-3547.
18. Clark W.M., Cohen B., Gibbs H.D. Studies on oxidation-reduction. VIII. Methylene blue. U. S. Pub Health Rep 1925, 40:1131-1201.
19. Coulibaly B., Zoungrana A., Mockenhaupt F.P., Schirmer R.H., Klose C., Mansmann U., Meissner P.E., Müller O. Strong gametocytocidal effect of methylene blue-based combination therapy against falciparum malaria: a randomised controlled trial. PLoS One 2009, 4:e5318.
20. Culo F., Sabolović D., Somogyi L., Marusić M., Berbiguier N., Galey L. Anti-tumoral and anti-inflammatory effects of biological stains. Agents Actions 1991, 34:424-428.
21. Deiana S., Harrington C.R., Wischik C.M., Riedel G. Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine. Psychopharmacology (Berl) 2009, 202:53-65.
22. Dietrich L.E., Price-Whelan A., Petersen A., Whiteley M., Newman D.K. The phenazine pyocyanin is a terminal signalling factor in the quorum sensing network of Pseudomonas aeruginosa. Mol. Microbiol 2006, 61:1308-1321.
23. Dietrich L.E., Teal T.K., Price-Whelan A., Newman D.K. Redox-active antibiotics control gene expression and community behavior in divergent bacteria. Science 2008, 321:1203-1206.
24. Ehrlich P. Über die Methylenblaureaktion der lebenden Nervensubstanz. Dtsch. Med. Wochenschr 1886, 12:49-52.
25. Ehrlich P., Leppmann A. Über Schmerzstillende Wirkung des Methylenblau. Dtsch. Med. Wochenschr 1890, 16:493-494.
26. Färber P.M., Arscott L.D., Williams C.H., Becker K., Schirmer R.H. Recombinant Plasmodium falciparum glutathione reductase is inhibited by the antimalarial dye methylene blue. FEBS Lett 1998, 422:311-314.
27. Fleischer B. Editorial: 100 years ago: Giemsa's solution for staining of plasmodia. Trop. Med. Int. Health 2004, 9:755-756.
28. Garcia-Lopez P., Garcia-Marin V., Freire M. The discovery of dendritic spines by Cajal in 1888 and its relevance in the present neuroscience. Prog. Neurobiol 2007, 83:110-130.
29. Gaudette N.F., Lodge J.W. Determination of methylene blue and leucomethylene blue in male and female Fischer 344 rat urine and B6C3F1 mouse urine. J. Anal. Toxicol 2005, 29:28-33.
30. Gura T. Hope in Alzheimer's fight emerges from unexpected places. Nat. Med 2008, 14:894.
31. Gut F., Schiek W., Haefeli W.E., Walter-Sack I., Burhenne J. Cation exchange resins as pharmaceutical carriers for methylene blue: binding and release. Eur. J. Pharm. Biopharm 2008, 69:582-587.
32. Guttmann P., Ehrlich P. Über die Wirkung des Methylenblau bei Malaria. Berlin. Klin. Woch 1891, 28:953-956.
33. Harvey B.H., Duvenhage I., Viljoen F., Scheepers N., Malan S.F., Wegener G., Brink C.B., Petzer J.P. Role of monoamine oxidase, nitric oxide synthase and regional brain monoamines in the antidepressant-like effects of methylene blue and selected structural analogues. Biochem. Pharmacol 2010, 80:1580-1591.
34. Hattori M., Sugino E., Minoura K., In Y., Sumida M., Taniguchi T., Tomoo K., Ishida T. Different inhibitory response of cyanidin and methylene blue for filament formation of tau microtubule-binding domain. Biochem. Biophys. Res. Commun 2008, 374:158-163.
35. Hendrickson W.A. Determination of macromolecular structures from anomalous diffraction of synchrotron radiation. Science 1991, 254:51-58.
36. Jeganathan S., von Bergen M., Mandelkow E.M., Mandelkow E. The natively unfolded character of tau and its aggregation to Alzheimer-like paired helical filaments. Biochemistry 2008, 47:10526-10539.
37. Jinwal U.K., Miyata Y., Koren J., Jones J.R., Trotter J.H., Chang L., O'Leary J., Morgan D., Lee D.C., Shults C.L., Rousaki A., Weeber E.J., Zuiderweg E.R., Gestwicki J.E., Dickey C.A. Chemical manipulation of hsp70 ATPase activity regulates tau stability. Neuroscience 2009, 29:12079-12088.
38. Juffermans N.P., Vervloet M.G., Daemen-Gubbels C.R.G., Binnekade J.M., de Jong M., Groeneveld A.B.J. A dose-finding study of methylene blue to inhibit nitric oxide actions in the hemodynamics of human septic shock. Nitric Oxide 2010, 22:275-280.
39. Khavandi A., Whitaker J., Gonna H. Serotonin toxicity precipitated by concomitant use of citalopram and methylene blue. Med. J. Aust 2008, 189:534-535.
40. Kossel A. Die Probleme der Biochemie. Universitäts-Buchdruckerei Heidelberg 1908.
41. Kristiansen J.E. Dyes, antipsychotic drugs, and antimicrobial activity. Fragments of a development, with special reference to the influence of Paul Ehrlich. Dan. Med. Bull 1989, 36:178-185.
42. Kühbacher M., Bartel J., Hoppe B., Alber D., Bukalis G., Bräuer A.U., Behne D., Kyriakopoulos A. The brain selenoproteome: priorities in the hierarchy and different levels of selenium homeostasis in the brain of selenium-deficient rats. J. Neurochem 2009, 110:133-142.
43. Kung H.F., Blau M. Regional intracellular pH shift: a proposed new mechanism for radiopharmaceutical uptake in brain and other tissues. J. Nucl. Med 1980, 21:147-152.
44. Kupfer A., Aeschlimann C., Wermuth B., Cerny T. Prophylaxis and reversal of ifosfamid encephalopathy with methylene-blue. Lancet 1994, 343:763-764.
45. Ludwig S., Baethge C. Lebensbedrohliche Kreislaufreaktionen auf Toluidinblau. Deutsches Ärzteblatt 2010, 107:C1308.
46. MacArthur D. Reminiscences 1964, and 2001, Bluejacket Books, Annapolis, MD. 2nd Edition.
47. Medina D.X., Caccamo A., Oddo S. Methylene blue reduces Abeta levels and rescues early cognitive deficit by increasing proteasome activity. Brain Pathol 2010, in press.
48. Mentes B.B., Akin M., Leventoglu S., Gultekin F.A., Oguz M. Intradermal methylene blue injection for the treatment of intractable idiopathic pruritus ani: results of 30 cases. Tech. Coloproctol 2004, 8:11-14.
49. Müller O., Meissner P., Schirmer R.H. Methylenblau in der Malariatherapie. Eine Alternative für Afrika?. Flugmed. Tropenmed. Reisemed. (FTR) 2008, 14:33-35.
50. Müller O., Sié A., Meissner P., Schirmer R.H., Kouyaté B. Artemisinin resistance on the Thai-Cambodian border. Lancet 2009, 374:1418-1419.
51. Naylor G.J., Martin B., Hopwood S.E., Watson Y. A two-year double-blind crossover trial of the prophylactic effect of methylene blue in manic depressive psychosis. Biol. Psychiatry 1986, 21:915-920.
52. Necula M., Breydo L., Milton S., Kayed R., van der Veer W.E., Tone P., Glabe C.G. Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization. Biochemistry 2007, 46:8850-8860.
53. Neugroschl J., Sano M. An update on treatment and prevention strategies for Alzheimer's disease. Curr. Neurol. Neurosci. Rep 2009, 9:368-376.
54. Neugroschl J., Sano M. Current treatment and recent clinical research in Alzheimer's disease. Mt Sinai. J. Med 2010, 77:3-16.
55. O'Leary J.L., Petty J., Harris A.B., Inukai J. Supravital staining of mammalian brain with intra-arterial methylene blue followed by pressurized oxygen. Stain Technol 1968, 43:197-201.
56. Oz M., Lorke D.E., Hasan M., Petroianu G.A. Cellular and molecular actions of methylene blue in the nervous system. Med. Res. Rev 2011, 31:93-117.
57. Oz M., Lorke D.E., Petroianu G.A. Methylene blue and Alzheimer's disease. Biochem. Pharmacol 2009, 78:927-932.
58. Pelgrims J., De Vos F., Van den Brande J., Schrijvers D., Prove A., Vermorken J.B. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br. J. Cancer 2000, 82:291-294.
59. Peter C., Hongwan D., Kupfer A., Lauterburg B.H. Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur. J. Clin. Pharmacol 2000, 56:247-250.
60. Pfaffendorf M., Bruning T.A., Batnik H.D., van Zwieten P.A. The interaction between methylene blue and the cholinergic system. Br. J. Pharmacol 1997, 122:95-98.
61. Pickhardt M., Larbig G., Khlistunova I., Coksezen A., Meyer B., Mandelkow E.M., Schmidt B., Mandelkow E. Phenylthiazolyl-hydrazide and its derivatives are potent inhibitors of tau aggregation and toxicity in vitro and in cells. Biochemistry 2007, 46:10016-10023.
62. Ramsay R.R., Dunford C., Gillman P.K. Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. Br. J. Pharmacol 2007, 152:946-951.
63. Riha P.D., Bruchey A.K., Echevarria D.J., Gonzalez-Lima F. Memory facilitation by methylene blue: dose-dependent effect on behavior and brain oxygen consumption. Eur. J. Pharmacol 2005, 511:151-158.
64. Sarma G.N., Savvides S.N., Becker K., Schirmer M., Schirmer R.H., Karplus P.A. Glutathione reductase of the malarial parasite Plasmodium falciparum: Crystal structure and inhibitor development. J. Mol. Biol 2003, 328:893-907.
65. Savvides S.N., Karplus P.A. Kinetics and crystallographic analysis of human glutathione reductase in complex with a xanthene inhibitor. J. Biol. Chem 1996, 271:8101-8107.
66. Schirmer R.H., Adler H., Zappe H.A., Gromer S., Becker K., Coulibaly B., Meissner P. Disulfide reductases as drug targets: methylene blue combination therapies for falciparum malaria in African children. Flavins and Flavoproteins 2008, 481-486. Prensas Universitarias de Zaragoza, Zaragoza, Spain.
67. Shanmugam G. Vasoplegic syndrome-the role of methylene blue. Eur. J. Cardiothorac. Surg 2005, 28:705-710.
68. Sutherland A.D., Faragher I.G., Frizelle F.A. Intradermal injection of methylene blue for the treatment of refractory pruritus ani. Colorectal Dis 2009, 11:282-287.
69. Tan C.D., Rodriguez E.R. Blue dye, green heart. Cardiovasc. Pathol 2010, 19:125-126.
70. Taniguchi S., Suzuki N., Masuda M., Hisanaga S., Iwatsubo T., Goedert M., Hasegawa M. Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J. Biol. Chem 2005, 280:7614-7623.
71. van Bebber F., Paquet D., Hruscha A., Schmid B., Haass C. Methylene blue fails to inhibit Tau and polyglutamine protein dependent toxicity in zebrafish. Neurobiol. Dis 2010, 39:265-271.
72. Van der Horst C., Stuebinger H., Seif C., Melchior D., Martinez-Portillo F.J., Juenemann K.P. Priapism - etiology, pathophysiology and management. Int. Braz. J. Urol 2003, 29:391-400.
73. Vennerstrom J.L., Makler M.T., Angerhofer C.K., Williams J.A. Antimalarial dyes revisited: xanthenes, azines, oxazines, and thiazines. Antimicrob. Agents Chemother 1995, 39:2671-2677.
74. Wainwright M., Amaral L. The phenothiazinium chromophore and the evolution of antimalarial drugs. Trop. Med. Int. Health 2005, 10:501-511.
75. Walter-Sack I., Rengelshausen J., Oberwittler H., Burhenne J., Müller O., Meissner P., Mikus G. High absolute bioavailability of methylene blue given as an aqueous oral formulation. Eur. J. Clin. Pharmacol 2009, 65:179-189.
76. Wang A.M., Morishima Y., Clapp K.M., Peng H.M., Pratt W.B., Gestwicki J.E., Osawa Y., Lieberman A.P. Inhibition of hsp70 by methylene blue affects signaling protein function and ubiquitination and modulates polyglutamine protein degradation. J. Biol. Chem 2010, 285:15714-15723.
77. Warth A., Goeppert B., Bopp C., Schirmacher P., Flechtenmacher C., Burhenne J. Turquoise to dark green organs at autopsy. Virchows Arch 2009, 454:341-344.
78. Wischik C.M., Bentham P., Wischik D.J., Seng K.M. Tau aggregation inhibitor (TAI) therapy with Rember™ arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks. Alzheimers Dement 2008, 4:T167.
79. Wischik C.M., Edwards P.C., Lai R.Y., Roth M., Harrington C.R. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:11213-11218.
80. Wolloch Y., Dintsman M. A simple and effective method of treatment for intractable pruritus ani. Am. J. Proctol. Gastroenterol. Colon Rect. Surg 1979, 30:34-36.
81. Yamashita M., Nonaka T., Arai T., Kametani F., Buchman V.L., Ninkina N., Bachurin S.O., Akiyama H., Goedert M., Hasegawa M. Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models. FEBS Lett 2009, 583:2419-2424.
82. Zoungrana A., Coulibaly B., Sié A., Walter-Sack I., Mockenhaupt F.P., Kouyate B., Schirmer R.H., Klose C., Mansmann U., Meissner P., Müller O. Safety and efficacy of methylene blue combined with artesunate or amodiaquine for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso. PLoS One 2008, 3:e1630.